Whitney Krey

Whitney Krey is an experienced biotechnology professional currently serving as Associate Director of Genome Editing Therapeutics (mRNA) at Metagenomi since June 2021, leading a therapeutic project in collaboration with Ionis. Prior roles at Metagenomi included Senior Scientist, where Krey led teams in mRNA therapeutic development and lipid nanoparticle production, significantly advancing gene editing therapeutics. Previously, Krey developed gene therapies for late-stage liver disease at Ambys Medicines and held various positions at Theravance Biopharma US, Inc., managing teams focused on drug discovery and clinical development in immunology. Krey's early career included research at Novartis Institutes for Biomedical Research, supporting novel antibiotic development. Krey holds a Master’s degree from the Massachusetts Institute of Technology and a Bachelor’s degree from Texas A&M University.